Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer.
Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R. Rapposelli IG, et al. Among authors: arcangeli v. BMC Cancer. 2021 May 26;21(1):611. doi: 10.1186/s12885-021-08368-5. BMC Cancer. 2021. PMID: 34034685 Free PMC article.
The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
Bogani G, Matteucci L, Tamberi S, Arcangeli V, Ditto A, Maltese G, Signorelli M, Martinelli F, Chiappa V, Leone Roberti Maggiore U, Perotto S, Scaffa C, Comerci G, Stefanetti M, Raspagliesi F, Lorusso D. Bogani G, et al. Among authors: arcangeli v. Int J Gynecol Cancer. 2017 Nov;27(9):1856-1862. doi: 10.1097/IGC.0000000000001108. Int J Gynecol Cancer. 2017. PMID: 29064913
Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study.
Raspagliesi F, Bogani G, Matteucci L, Casarin J, Sabatucci I, Tamberi S, Arcangeli V, Maltese G, Lepori S, Comerci G, Stefanetti M, Ditto A, Martinelli F, Chiappa V, Lorusso D. Raspagliesi F, et al. Among authors: arcangeli v. Int J Gynecol Cancer. 2018 Nov;28(9):1706-1713. doi: 10.1097/IGC.0000000000001286. Int J Gynecol Cancer. 2018. PMID: 30376554
RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Bogani G, Matteucci L, Tamberi S, Ditto A, Sabatucci I, Murgia F, Arcangeli V, Maltese G, Comerci G, Stefanetti M, Sonetto C, Calareso G, Marchiano A, Chiappa V, Lorusso D, Raspagliesi F. Bogani G, et al. Among authors: arcangeli v. Eur J Obstet Gynecol Reprod Biol. 2019 Jun;237:93-99. doi: 10.1016/j.ejogrb.2019.04.007. Epub 2019 Apr 8. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31029972
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, Oliveira C, Morgagni P, Saragoni L, Bencivenga M, Ulivi P, Amadori D, Martinelli G, Falcini F, Ranzani GN, Calistri D. Tedaldi G, et al. Among authors: arcangeli v. Cancers (Basel). 2019 Sep 11;11(9):1340. doi: 10.3390/cancers11091340. Cancers (Basel). 2019. PMID: 31514334 Free PMC article.
Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer.
Tedaldi G, Molinari C, São José C, Barbosa-Matos R, André A, Danesi R, Arcangeli V, Ravegnani M, Saragoni L, Morgagni P, Rebuzzi F, Canale M, Pignatta S, Ferracci E, Martinelli G, Ranzani GN, Oliveira C, Calistri D, Ulivi P. Tedaldi G, et al. Among authors: arcangeli v. Pharmaceuticals (Basel). 2021 May 12;14(5):457. doi: 10.3390/ph14050457. Pharmaceuticals (Basel). 2021. PMID: 34066170 Free PMC article.
53 results